What's Next for Abbott in IVD?

Abbott and GE Healthcare broke off their $8.13 billion deal for Abbott's diagnostics and point-of-care businesses. The difficulty of delivering something so heavily integrated into Abbott appears to have surprised both sides. It's unlikely Abbott will seek another buyer and it is poised to make new investments in diagnostics. GE is also likely to continue pursuing more targeted acquisitions in diagnostics including, like Abbott, in molecular testing.

On July 11, Abbott Laboratories Inc. and the GE Healthcare division of General Electric Co. told the world that their $8.13 billion all-cash deal to transfer Abbott Diagnostics, Abbott’s immunoassay, clinical chemistry, and hematology businesses (known collectively as ADD) and Abbott Point of Care, its point-of-care (POC) testing business, was off. [See Deal] And if Abbott’s account of the break-up--for which it will not receive a fee from GE--is the whole story, it’s unlikely that it will be looking for another buyer for those businesses.

"There were literally thousands of transition services agreements that the parties were going to have to enter into," explains Ed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.